First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients
A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or refractory multiple myeloma, has dosed its first patient, SpringWorks announced. The safety and preliminary effectiveness of this combination are being assessed as a sub-study in…